The predictive role of peripheral blood immune cell subsets in the immune-related adverse events for non-small cell lung cancer
JIANG Xu
CHEN Jiana
YANG Huaxia
Abstract：Objective To evaluate the predictive value of baseline peripheral blood immune cell profiles for immune-related adverse events(irAEs)following immune checkpoint inhibitors(ICIs)therapy for non-small cell lung cancer(NSCLC)patients.Methods In total,45 NSCLC patients who received ICIs treatment between December 2023 and December 2024 were enrolled.Patients were stratified into irAE(n=19)and non-irAE(n=26)groups based on irAE occurrence during treatment.Pre-treatment peripheral blood samples were collected,and flow cytometry was used to quantify immune subset proportions and activation marker expression.Receiver operating characteristic(ROC)curves were used to evaluate the predictive value of individual cellular markers for irAE development in NSCLC patients after immunotherapy.Results The irAE group exhibited significantly reduced proportion of intermediate monocytes(CD14+CD16+),as compared with the non-irAE group(P<0.05).The expression of CD69,an early activation marker,in CD3+T lymphocytes and the expression of CD154,an early activation marker,in CD8+T lymphocytes were both significantly lower in the irAE group than in the non-irAE group(P<0.05).ROC analysis demonstrated better predictive performance of the three-marker panel(intermediate monocytes/CD69+CD3+T cells and CD154+CD8+T cells;AUC=0.778)compared with individual biomarkers.Conclusion Lower levels of intermediate monocytes,CD69+CD3+T cells,and CD154+CD8+T cells in baseline peripheral blood may serve as potential biomarkers for predicting irAE development in NSCLC patients after immunotherapy.
Keywords：non-small cell lung cancerimmune checkpoint inhibitorsimmune-related adverse eventsimmune cell subsets
Publication Date：2025-07-28
Online Publishing Date：2025-10-28(First online date of this platform, not the publication date of the document)
Pages：6( 495-500 )